Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,727.04 +64.04 (+0.11%) CMC Crypto 200
1,262.78 -21.04 (-1.64%)
Omega Therapeutics, Inc. (OMGA)
After hours:
| Previous close | 2.2400 |
| Open | 2.2700 |
| Bid | 2.0700 x 400 |
| Ask | 2.1200 x 400 |
| Day's range | 2.0700 - 2.3000 |
| 52-week range | 1.3000 - 6.3000 |
| Volume | |
| Avg. volume | 477,920 |
| Market cap | 114.171M |
| Beta (5Y monthly) | 1.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensingCAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kender’s industry knowledge a
- GlobeNewswire
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences. Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 9:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare ConferenceDate: Monday, June 10, 2024Tim
- GlobeNewswire
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. “Kaan is an acco
